Best SurfingNASH.com Podcasts (2025)

1
S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism 37:13

Play Pause

18d ago37:13

37:13

Send us a text This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Roger drives this conversation, focusing on two very different, yet very important is…

1
S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease 20:19

20d ago20:19

20:19

Send us a text Last month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag a…

1
S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management 19:48

20d ago19:48

19:48

Send us a text This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) in…

1
S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health 1:13:53

25d ago1:13:53

1:13:53

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 -…

1
S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy? 21:39

27d ago21:39

21:39

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and con…

1
S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices 22:58

29d ago22:58

22:58

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment…

1
S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy 24:35

29d ago24:35

24:35

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices. Thi…

1
6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US 1:04:23

1M ago1:04:23

1:04:23

Send us a text 00:00:00 - Surf's Up, Season 6, Episode 12 This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having …

1
6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative 41:03

1M ago41:03

41:03

Send us a text This week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiative, why she believe it should be titled "CKLM" for liver, and how including liver in the CK…

1
6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach 43:59

1M ago43:59

43:59

Send us a text Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the second of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. This conversation starts by focusing on how the two…

1
6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics 37:34

1M ago37:34

37:34

Send us a text Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly gr…

1
6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases 1:49:45

2M ago1:49:45

1:49:45

Send us a text 00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed…

1
6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients 37:16

2M ago37:16

37:16

Send us a text This week's expert is Tim Jobson, Medical Director of Predictive Health Intelligence, a UK-based consultancy. Tim joins Louise Campbell and Roger Green to share an update on PHI's Somerset UK project and other activities. The Somerset pilot was designed to help the NHS identify untreated patients at high risk for liver disease and br…

1
6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic 30:49

2M ago30:49

30:49

Send us a text Roger Green talks with LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos about the launch of LiverRight, America's first virtual hepatology clinic, which has recently begun treating patients. Brandon starts the conversation by telling the story of how he and his partner, Pete Celano, started LiverRight: they saw …

1
6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans 27:36

2M ago27:36

27:36

Send us a text This conversation is the first segment of SurfingMASH’s July discussion of key events from the first six months of 2025. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green each chose one topic of personal interest. Today, Jörn Schattenberg discusses two recent papers that demonstrate differences in how individual patients re…

1
6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening 1:32:25

2M ago1:32:25

1:32:25

Send us a text 00:00 - Surf's Up 6.10.1 This conversation covers three topics. Jörn Schattenberg discusses two papers that suggest an exciting role NITs might play in future prescribing decisions, two executives from LiverRight describe the U.S.'s first virtual liver clinic, and Tom Jobson of Predictive Health Intelligence updates us on how simple …

1
6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research 29:12

2M ago29:12

29:12

Send us a text Hepatologist and hepatology key opinion leader Naim Alkhouri joins Roger Green to remember his longstanding relationship with Stephen Harrison, announce his new role as Chief Academic Officer at Summit Clinical Research and share how, in this role, he will have exciting new avenues make an impact on many elements of MASH drug develop…

1
6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge 39:31

2M ago39:31

39:31

Send us a text Fatty Liver Alliance President Mike Betel joins Roger Green to discuss his recent completion of the 3rd Annual Glucose Challenge, an event every July where Mike wears a continuous glucose monitor (CGM) device for a month, conducts food experiments, tracks glucose levels and shares all results with his LinkedIn and FattyLiver.ca frien…

1
6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play 23:35

2M ago23:35

23:35

Send us a text This conversation is the third and final segment of SurfingMASH’s July discussion of #SLDThinkTank 2025. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include Dr. Kristina Curtis of Applied Behaviour Change, a UK-based consultancy. Louise begins this conversation by highlighting the low level o…

1
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd 1:17:21

2M ago1:17:21

1:17:21

Send us a text 00:00:00 - Surf's Up: Episode 6.9 This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 days, and the third celebrates the late Stephen Harrison while looking into the future of clin…

1
6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects 16:59

2M ago16:59

16:59

Send us a text This conversation is the fourth and final segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, …

1
6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed 31:08

2M ago31:08

31:08

Send us a text Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss recent Washington political and regulatory activities, their potential impact on the liver community, and ways we can respond. Larry starts by acknowledging that we are in for "dark times" under the current administration and describes some current gov…

1
6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change 16:40

2M ago16:40

16:40

Send us a text This conversation is the second segment of SurfingMASH's coverage of the Global Think Tank on Steatotic Liver Diseases (#SLDThinkTank2025) held in Barcelona in June. It focuses on the kinds of feedback most likely to produce successful behavioral interventions. The conversation begins with Jörn discussing the Liver Screen Study, a "v…

1
6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment 1:02:58

2M ago1:02:58

1:02:58

Send us a text 00:00 - Surf's Up, Season 6 Episode 8 The conversation addresses three issues that are distinct, yet each is pivotal to the future of MASLD and MASH therapies. The first, from the Global Think-Tank on Steatotic Liver Disease, considers how personal and digital approaches can be combined to form the most effective strategy for patient…

1
S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development 14:55

2M ago14:55

14:55

Send us a text This conversation is the third segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. Louise starts the discussion by asking when…

1
S6 - E7.2 - Patient Advocate Jose Willemse on Patient-Centered Care 33:45

2M ago33:45

33:45

Send us a text This week's newsmaker, Dutch Liver Patients Association President Jose Willemse, joins Roger Green to discuss the patient screening program at this year's EASL Congress, which took place in Amsterdam, and the general idea of what constitutes a patient-sensitive dialogue. Jose describes the phenomenal level of interest in the screenin…

1
S6 - E7.1 - #SLDThinkTank2025 Part I: Hybrid Interventions Integrate AI and Human Care 22:33

2M ago22:33

22:33

Send us a text This conversation is the opening segment of SurfingMASH's coverage of the Global Think Tank on Steatotic Liver Diseases (#SLDThinkTank2025) held in Barcelona in June. Co-hosts Louise Campbell and Roger Green are joined by Dr. Kristina Curtis, Managing Director of Applied Behaviour Change, a UK-based consultancy. This discussion start…

1
S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development 1:09:20

2M ago1:09:20

1:09:20

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 7 Host Roger Green explains our recent vacation from publishing episodes, assures the audience that the podcast will continue weekly for months and years ahead, and discusses the episode's sections, covering the Global Think-Tank on Steatotic Liver Disease (SLD), the EASL patient screening activ…

1
S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH 57:17

5M ago57:17

57:17

Send us a text 00:00:00 Surf's Up, Season 6, Episode 6. On April 23, 2024, our colleague and co-founder, Stephen Harrison, passed away suddenly. This week, Surfing the MASH Tsunami remembers Stephen with two of his closest associates and continues our annual MASH Drug Development roundtable held in his honor. 00:00:04:24 - A Deep Dive into Drug Dev…

1
S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom 26:18

5M ago26:18

26:18

Send us a text This weekend’s Newsmaker, Indiana University hepatologist and key opinion leader Naga Chalasani, joins Roger Green to discuss Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting, an article his group published recently in Hepatology Communications. He shares highlights …

1
S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science 23:23

5M ago23:23

23:23

Send us a text This week’s expert, Hepatologist and Key Opinion Leader Scott Friedman, joins Roger to discuss advances in acceptance of gene therapy and knowledge in other areas of basic liver science. When discussing science, he pays particular attention to findings on the diversity of stellate cells and his interest in CAR-T as a therapy for live…

1
S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis 24:24

5M ago24:24

24:24

Send us a text This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. This opening discussion focuses on exci…

1
S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies 1:09:00

5M ago1:09:00

1:09:00

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 5 Host Roger Green briefly describes this episode’s three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part One The opening portion of this month's roundtable centers around two issues: exciting d…

1
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment 24:34

6M ago24:34

24:34

Send us a text This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-2…

1
S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates 31:16

6M ago31:16

31:16

Send us a text This weekend's Newsmaker, Fatty Liver Alliance Founder Mike Betel, joins Roger Green to discuss the wide range of conferences where he has been invited to speak or sit on a panel this year. Specifically, he shares his belief on what this says about interest in MASLD and describes the messages he delivers at the conferences he attends…

1
S6 - E4.1 - MASLD Drugs, SLD Spectrum Insights Suggest Bright Future 20:58

6M ago20:58

20:58

Send us a text This conversation is the concluding segment of SurfingMASH's coverage of the AASLD Emerging Trends Conference on the SLD Spectrum diseases: MASLD, MetALD and ALD. In addition to co-hosts Louise Campbell and Roger Green, panelists include EASL Secretary General Aleksander Krag, hepatologist Alex Lalos and Jenn Leigh Jones, Founder of …

1
S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy 1:12:42

6M ago1:12:42

1:12:42

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Live…

1
S6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugs 31:31

6M ago31:31

31:31

Send us a text This week's Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT, HistoIndex's new digital pathology service for clinical practice. Highlight: Recent job cu…

1
S6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the Clinic 28:57

6M ago28:57

28:57

Send us a text This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT resu…

1
S6- E3.1 - Roundtable: Spotting Tomorrow’s Trends in Today's MASLD Studies 15:02

6M ago15:02

15:02

Send us a text Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical trial questions. Guest Surfers include Professor Aleksander Krag of…

1
S6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves 1:12:31

6M ago1:12:31

1:12:31

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 3 Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical trial questions. Our newsm…

1
S6 - E2 - MetALD Epidemiology, MASLD Mortality and a PCP "Unicorn" 1:11:36

6M ago1:11:36

1:11:36

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 2 Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on disease epidemiology and what it can teach us about the relative importance of alcohol and diet on disease progression. Our newsmaker, hepatology …

1
S6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom 1:13:24

6M ago1:13:24

1:13:24

Send us a text 00:00:00 - Surf's Up! Season 6 Episode 1 SurfingMASH kicks off our sixth season in our new format, with three major elements to each episode. This week's Roundtable and Newsmakers segments focused on two recent conferences that took a multispecialty perspective on the range of medical and psychological issues affecting steatotic live…

1
S5 - E26.5 - Looking Back at #TLM2024 - Promoting Healthy Livers and Looking Ahead to 2025 15:18

9M ago15:18

15:18

Send us a text In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews two sessions promoting healthy livers and asks panelists what they anticipate for #TLM2025. This last conversation starts with Jeff describing the session…

1
S5 - E26.4 - Looking Back at #TLM2024 - Patient Advocacy and Patient-Centric Trials 11:44

9M ago11:44

11:44

Send us a text In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers the role of patient advocacy in replacing biopsy in clinical trials with NITs and reviews a session on the foundational principles for patien-centric cl…

1
S5 - E26.2 - Looking Back at #TLM2024 - Patient Genotyping and MASH Clusters 14:27

9M ago14:27

14:27

Send us a text In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers how the anticipated approval of a second MASH drug without biopsy might affect clinical trials and discusses two recent publications on patient genotypi…

1
S5 - E26.3 - Looking Back at #TLM2024 - FGF-21 Agents and the FDA Corner 13:18

9M ago13:18

13:18

Send us a text In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the late-breaker presentation on efimosermin, a q4w FGF-21 agent and the "FDA Corner" session. Jörn begins the discussion by highlighting a paper from the…

1
S5 - E26.1 - Looking Back at #TLM2024 - Semaglutide Passes the ESSENCE Test 13:32

9M ago13:32

13:32

Send us a text In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the ESSENCE trial, the Phase 3 trial demonstrating that semaglutide regresses fibrosis levels in some MASH patients. The conversation begins with each pan…

1
S5-26 - One Month Later: Looking Back at MASLD/MASH Coverage From The Liver Meeting 2024 1:11:25

9M ago1:11:25

1:11:25

Send us a text 00:00:00 – Surf’s Up: Season 5 Episode 26 - Last month, close to 8,000 hepatology stakeholders convened in San Diego for The Liver Meeting 2024. Hepatology Key Opinion Leader Naim Alkhouri, Novo Nordisk International Vice President for Medicines Michelle Long, and patient advocates Jeff McIntyre from the Global Liver Institute and Mi…

1
S5 - E25 - Reviewing Expert Recommendations on the Use of Resmetirom 42:02

1y ago42:02

42:02

Send us a text 00:00:00 - Surf's Up: Season 5 Episode 25 On July 20, Clinical Gastroenterology and Hepatology released the paper, Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to non-cirrhotic Advanced Fibrosis. Corresponding author Maru Rinella joins t…